Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Cellular effects of LRRK2 mutations.

Cookson MR.

Biochem Soc Trans. 2012 Oct;40(5):1070-3. Review.

2.

The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.

Rudenko IN, Kaganovich A, Hauser DN, Beylina A, Chia R, Ding J, Maric D, Jaffe H, Cookson MR.

Biochem J. 2012 Aug 15;446(1):99-111. doi: 10.1042/BJ20120637.

3.

LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.

Xiong Y, Dawson VL, Dawson TM.

Biochem Soc Trans. 2012 Oct;40(5):1074-9. Review.

4.

Contribution of GTPase activity to LRRK2-associated Parkinson disease.

Tsika E, Moore DJ.

Small GTPases. 2013 Jul-Sep;4(3):164-70. doi: 10.4161/sgtp.25130. Epub 2013 Jun 10. Review.

5.

Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.

Greggio E, Cookson MR.

ASN Neuro. 2009 Apr 14;1(1). pii: e00002. doi: 10.1042/AN20090007. Review.

6.

Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.

Greggio E.

Biochem Soc Trans. 2012 Oct;40(5):1058-62. Review.

PMID:
22988865
7.

Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies.

Skibinski G, Nakamura K, Cookson MR, Finkbeiner S.

J Neurosci. 2014 Jan 8;34(2):418-33. doi: 10.1523/JNEUROSCI.2712-13.2014.

8.

LRRK2 pathobiology in Parkinson's disease.

Martin I, Kim JW, Dawson VL, Dawson TM.

J Neurochem. 2014 Dec;131(5):554-65. doi: 10.1111/jnc.12949. Epub 2014 Oct 10. Review.

9.

Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.

Gandhi PN, Chen SG, Wilson-Delfosse AL.

J Neurosci Res. 2009 May 1;87(6):1283-95. doi: 10.1002/jnr.21949. Review.

10.

Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain.

Civiero L, Cirnaru MD, Beilina A, Rodella U, Russo I, Belluzzi E, Lobbestael E, Reyniers L, Hondhamuni G, Lewis PA, Van den Haute C, Baekelandt V, Bandopadhyay R, Bubacco L, Piccoli G, Cookson MR, Taymans JM, Greggio E.

J Neurochem. 2015 Dec;135(6):1242-56. doi: 10.1111/jnc.13369. Epub 2015 Oct 19.

11.

The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.

Cookson MR.

Nat Rev Neurosci. 2010 Dec;11(12):791-7. doi: 10.1038/nrn2935. Epub 2010 Nov 19. Review.

12.

Biochemical and pathological characterization of Lrrk2.

Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ, Van Deerlin VM.

Ann Neurol. 2006 Feb;59(2):315-22.

PMID:
16437584
13.

LRRK2 Parkinson's disease: from animal models to cellular mechanisms.

Lin CH, Tsai PI, Wu RM, Chien CT.

Rev Neurosci. 2011;22(4):411-8. doi: 10.1515/RNS.2011.036. Epub 2011 Jun 17. Review.

PMID:
21679126
14.

Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.

Henry AG, Aghamohammadzadeh S, Samaroo H, Chen Y, Mou K, Needle E, Hirst WD.

Hum Mol Genet. 2015 Nov 1;24(21):6013-28. doi: 10.1093/hmg/ddv314. Epub 2015 Aug 6.

PMID:
26251043
15.

Mutations in LRRK2 as a cause of Parkinson's disease.

Giasson BI, Van Deerlin VM.

Neurosignals. 2008;16(1):99-105. Epub 2007 Dec 5. Review.

PMID:
18097165
16.

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q, Lee JD, Patricelli MP, Nomanbhoy TK, Alessi DR, Gray NS.

Nat Chem Biol. 2011 Apr;7(4):203-5. doi: 10.1038/nchembio.538. Epub 2011 Mar 6.

17.

Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.

Lu YW, Tan EK.

J Neurosci Res. 2008 Jul;86(9):1895-901. doi: 10.1002/jnr.21656. Review.

PMID:
18338801
18.

Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.

Tsika E, Nguyen AP, Dusonchet J, Colin P, Schneider BL, Moore DJ.

Neurobiol Dis. 2015 May;77:49-61. doi: 10.1016/j.nbd.2015.02.019. Epub 2015 Feb 28.

PMID:
25731749
19.

Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.

Sheng Z, Zhang S, Bustos D, Kleinheinz T, Le Pichon CE, Dominguez SL, Solanoy HO, Drummond J, Zhang X, Ding X, Cai F, Song Q, Li X, Yue Z, van der Brug MP, Burdick DJ, Gunzner-Toste J, Chen H, Liu X, Estrada AA, Sweeney ZK, Scearce-Levie K, Moffat JG, Kirkpatrick DS, Zhu H.

Sci Transl Med. 2012 Dec 12;4(164):164ra161. doi: 10.1126/scitranslmed.3004485.

20.

[Molecular basis of Parkinson's disease linked with mutations in the LRRK2 gene].

Pchelina SN, emel'ianov AK, Usenko TS.

Mol Biol (Mosk). 2014 Jan-Feb;48(1):3-14. Review. Russian.

PMID:
25842821

Supplemental Content

Support Center